CALTX — Calliditas Therapeutics AB Cashflow Statement
0.000.00%
HealthcareMid Cap
- SEK11.16bn
- SEK11.37bn
- SEK1.21bn
Annual cashflow statement for Calliditas Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -28 | -380 | -524 | -422 | -373 |
Depreciation | |||||
Non-Cash Items | 0.486 | 15.5 | 66.7 | 48.3 | 53.8 |
Other Non-Cash Items | |||||
Changes in Working Capital | -45.3 | 55.1 | -3.81 | 49.3 | -164 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -71 | -309 | -462 | -311 | -435 |
Capital Expenditures | -16.2 | — | -22.7 | -2.51 | -12.8 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -1.89 | -173 | -1.69 | -2.63 | -0.957 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -18.1 | -173 | -24.3 | -5.14 | -13.7 |
Financing Cash Flow Items | -12.7 | -178 | -67.9 | -0.001 | -0.001 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 199 | 769 | 435 | 576 | 200 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 107 | 243 | -40.8 | 294 | -275 |